Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET

Trial Profile

Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2018

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome; Neuroendocrine tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 May 2018 According to the Lexicon Pharmaceuticals media release, company anticipate to initiate this trial in 2H of 2018.
    • 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 30 Apr 2018.
    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top